Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiarrhythmic therapy in heart failure.

Lars Eckardt1, Wilhelm Haverkamp, Günter Breithardt

  • 1Hospital of the Westfälische Wilhelms-University, Department of Cardiology and Institute for Arteriosclerosis Research, Münster, Germany.

Heart Failure Monitor
|March 14, 2003
PubMed
Summary

Sudden cardiac death in heart failure is often caused by ventricular tachycardia (VT). Implantable cardioverter-defibrillators (ICDs) effectively prevent sudden cardiac death in patients with VT, regardless of heart failure severity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease.

Journal of the American College of Cardiology·2026
Same author

Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

Safety and efficacy of amiodarone and dronedarone for early rhythm control in EAST-AFNET 4.

Clinical research in cardiology : official journal of the German Cardiac Society·2025
Same author

Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin-K antagonists: A retrospective German claims data analysis.

Journal of internal medicine·2024
Same author

Biomarker-based prediction of sinus rhythm in atrial fibrillation patients: the EAST-AFNET 4 biomolecule study.

European heart journal·2024

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Heart failure is a complex cardiovascular syndrome with high mortality.
  • Sudden cardiac death, primarily due to ventricular tachycardia (VT), accounts for about 50% of deaths in heart failure patients.
  • Arrhythmias like VT and bradyarrhythmias are significant complications, influenced by underlying ischemia and structural changes.

Purpose of the Study:

  • To review the mechanisms of arrhythmogenesis in heart failure.
  • To discuss the role of optimal heart failure management and antiarrhythmic therapies.
  • To highlight the efficacy of implantable cardioverter-defibrillators (ICDs) in preventing sudden cardiac death.

Main Methods:

  • Review of existing literature on heart failure, arrhythmias, and sudden cardiac death.

Related Experiment Videos

  • Analysis of mechanisms contributing to arrhythmogenesis, including re-entrant circuits and calcium metabolism.
  • Evaluation of therapeutic strategies, including medical management and device therapy.

    • Main Results:

    • Re-entrant mechanisms and altered calcium handling are key contributors to arrhythmias in heart failure.
    • Optimal medical therapy (revascularization, beta-blockers, ACE inhibitors) is crucial for managing heart failure.
    • Implantable cardioverter-defibrillators (ICDs) are highly effective in preventing sudden cardiac death from VT, especially in patients with sustained VT or resuscitation history.

    Conclusions:

    • Effective management of heart failure and its underlying causes is paramount.
    • ICDs provide significant protection against sudden cardiac death in high-risk heart failure patients.
    • Additional antiarrhythmic therapy may be necessary for managing other arrhythmias like atrial fibrillation in conjunction with ICDs.